false
0001557376
0001557376
2024-03-04
2024-03-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
March 4, 2024
ZEO SCIENTIFIX, INC.
(Exact name of registrant as specified in its charter)
Nevada |
|
000-55008 |
|
47-4180540 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
3321 College Avenue,
Suite 246
Davie, Florida |
|
33314 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (888) 963-7881
____________________________________________
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ☐ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each Class |
|
Trading Symbol |
|
Name of each exchange on which registered |
None |
|
N/A |
|
N/A |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As used in this Current Report on Form 8-K (this
“Report”), and unless otherwise indicated, the terms “the Company,” “Zeo,” “we,”
“us” and “our” refer to Zeo ScientifiX, Inc. f/k/a/ Organicell Regenerative Medicine, Inc. and its
subsidiaries.
Item 8.01 Other Events.
On March 4, 2024, the Company issued a press release
announcing that the Financial Industry Regulatory Authority (“FINRA”) had completed the review and processing of the
Company’s Issuer Company-Related Action Notification Form, which was submitted to FINRA in connection with the change of our corporate
name from “Organicell Regenerative Medicine, Inc.” to “Zeo ScientifiX, Inc.” (which was effective
February 20, 2024) and the change in our OTCQB trading symbol from “OCEL” to “ZEOX,” which will
be effective with the opening of trading on March 5, 2024.
A copy of the press release is attached as Exhibit
99.1 to this Report.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 4, 2024 |
ZEO SCIENTIFIX, INC. |
|
|
|
|
By: |
/s/ Harry Leider |
|
|
Harry Leider, M.D. |
|
|
Chief Executive Officer |
Exhibit
99.1
ORGANICELL
REGENERATIVE MEDICINE REBRANDING TO ZEO SCIENTIFIX
Leading
Therapeutics Research Company Begins New Era
Common
Stock to trade on OTCQB under the symbol “ZEOX” commencing March 5, 2024
Fort Lauderdale, Florida – March 4, 2024 –
ZEO ScientifiX, Inc. (OTCQB: ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. – OTCQB: OCEL) today reported that the Financial
Industry Regulatory Agency (“FINRA”) completed the processing of the Company’s Corporate Action Notification
Form filed with respect to the change of its name from Organicell Regenerative Medicine, Inc. to “ZEO ScientifiX, Inc.”
(“ZEO” or the “Company”) and its stock trading symbol from OCEL to “ZEOX” (the
“Corporate Action”). The Corporate Action is effective as of the opening of trading, tomorrow, March 5, 2024. In
connection with the Corporate Action, the CUSIP number for our common stock will not change.
ZEO
ScientifiX’s Chief Executive Officer, Harry Leider, MD, MBA commented, “We are delighted about our name change to ZEO as
it communicates the energy and creativity inherent in our growing organization. Having recently competed our Phase 1 clinical program,
we are eager to move forward to commence and complete our Phase 2 trials, leading us closer to potential FDA approval of our proprietary
biologic therapeutics - as well as to continue to grow our flagship product, a first-of-its-kind completely autologous exosome called,
Patient Pure X™ (PPX™).”
ZEO
is a biopharmaceutical company with an R & D program targeted at chronic diseases utilizing novel biological therapeutics. The Company
is focused on providing patients access to advanced regenerative therapies as quickly as possible through the rigor of its advanced research
programs. The Company recently made several additions to its executive team, adding multiple health care leaders with broad backgrounds
in regenerative medicine, commercial healthcare, and the biopharma space.
Dr.
Leider added, “The progress of our research program and the additions to our leadership team should provide the biotech community
with enhanced confidence in ZEO ScientifiX and our future – as we advance to a future where
innovative biologic therapeutics will redefine the standard of care for many important chronic diseases.”
About
ZEO ScientifiX, Inc.
ZEO
ScientifiX, Inc. (OTCQB: ZEOX) is a clinical-stage biopharmaceutical company located inside Nova Southeastern University’s
Collaborative Center for Research in Davie, Florida. ZEO is principally focusing on the development of innovative biological therapeutics
for the treatment of chronic diseases and the provision of related services. The Company’s proprietary products are derived from
allogenic and autologous sources and are manufactured in an FDA-registered, cGMP compliant laboratory to retain the naturally occurring
bioactive exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent.
To
learn more, please visit https://zeoscientifix.com/
Forward-Looking
Statements
Certain
statements contained in this press release, including those regarding its R&D program should be considered forward-looking statements
within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of
1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are often identified by the use of forward-looking terminology such as “will,” “believes,” “expects,”
“potential,” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that
the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. No assurances can be given that the Company will be successful in its research initiatives.
In addition, no assurances can be given that our research initiatives will increase the price of our common stock to a level that is
attractive to brokerage houses and institutional investors. We remind you that actual results could vary dramatically as a result of
known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition,
the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies,
success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or
regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other
intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk
factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov).
You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the
Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included
in this press release may change over time and may or may not be accurate after the date of the release. ZEO has no intention and specifically
disclaims any duty to update the information in this press release.
Investor
Relations and Media Relations Contact
ZEO
Investor Relations
Jacqueline
Domenech
1-888-963-7881
IR@zeoscientifix.com
v3.24.0.1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Organicell Regenerative ... (QB) (USOTC:OCELD)
Historical Stock Chart
From May 2024 to Jun 2024
Organicell Regenerative ... (QB) (USOTC:OCELD)
Historical Stock Chart
From Jun 2023 to Jun 2024